Showing 20 of 49 recruiting trials for “extranodal-nasal-nkt-cell-lymphoma”
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
RecruitingNCT06534463 ↗
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
👨⚕️ Bing Xu, The First Aiffiliated hosptical of xiamen University📍 1 site📅 Started Jun 2024View details ↗
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
RecruitingNCT06362148 ↗
Circulating Tumor DNA in Peripheral T-cell Lymphomas
👨⚕️ Francesco A d'Amore, MD, DMSc, Aarhus University Hospital and Aarhus University📍 1 site📅 Started Mar 2024View details ↗
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
👨⚕️ Jun Shi, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University📍 1 site📅 Started Nov 2023View details ↗
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
👨⚕️ Catherine THIEBLEMONT, Pr, Lymphoma Study Association📍 48 sites📅 Started Sep 2023View details ↗
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →